Furthermore, Western blotting analysis demonstrated that in the 15/30 glioma samples with SLC22A18 promoter methylation, SLC22A18 protein expression was significantly decreased compared to the adjacent normal brain tissue (Figure 3C). This evidence concerns the gene SLC67A1 and central nervous system cancer.